ArticleThe Journal of biological chemistry2016
Mucosal Administration of Collagen V Ameliorates the Atherosclerotic Plaque Burden by Inducing Interleukin 35-dependent Tolerance.
Article in The Journal of biological chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Distinct genetic architecture of coronary heart disease in dyslipidemia patients.BMC medical genomics · 2026Article
- Temporal Dynamics of Pulmonary Fibrosis and Immune Dysregulation in a Collagen V-Driven Systemic Sclerosis Model.International journal of molecular sciences · 2025Article
- The Relationship Between Cholesterol Level, Cytokine Profile, and Arterial Stiffness in Young Patients with Uncomplicated Type 1 Diabetes.International journal of molecular sciences · 2025Article
- Investigation for atherosclerotic plaque rupture with thrombosis in mice based on single-cell sequencing and bioinformatics analysis.Frontiers in cardiovascular medicine · 2025Article
- Immunomodulatory effects of iTr35 cell subpopulation and its research progress.Clinical and experimental medicine · 2024Review
- Immunotherapeutic potential of collagen V oral administration in mBSA/CFA-induced arthritis.PloS one · 2024Article
- Type V collagen-induced nasal tolerance prevents lung damage in an experimental model: new evidence of autoimmunity to collagen V in COPD.Frontiers in immunology · 2024Article
- Interleukin-35: Structure, Function and Its Impact on Immune-Related Diseases.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2021Review
- Donor HLA-DR Drives the Development of De Novo Autoimmunity Following Lung and Heart Transplantation.Transplantation direct · 2020Article
- Treg-Cell-Derived IL-35-Coated Extracellular Vesicles Promote Infectious Tolerance.Cell reports · 2020Article
- Identification of Autoimmunity to Peptides of Collagen V α1 Chain as Newly Biomarkers of Early Stage of Systemic Sclerosis.Frontiers in immunology · 2020Article
- Infectious Tolerance as Seen With 2020 Vision: The Role of IL-35 and Extracellular Vesicles.Frontiers in immunology · 2020Review
- Proposition of a novel animal model of systemic sclerosis induced by type V collagen in C57BL/6 mice that reproduces fibrosis, vasculopathy and autoimmunity.Arthritis research & therapy · 2019Article
- Leukocyte-Associated Ig-like Receptor 1 Inhibits TJournal of immunology (Baltimore, Md. : 1950) · 2018Article
- Specific Donor HLA-DR Types Correlate With Altered Susceptibility to Development of Chronic Lung Allograft Dysfunction.Transplantation · 2018Article
- Collagen V oral administration decreases inflammation and remodeling of synovial membrane in experimental arthritis.PloS one · 2018Article
- Th17 Responses to Collagen Type V, kα1-Tubulin, and Vimentin Are Present Early in Human Development and Persist Throughout Life.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017Article
- Cardiac Autoimmunity: Myocarditis.Advances in experimental medicine and biology · 2017Review
- Kinetics of Alloantigen-Specific Regulatory CD4 T Cell Development and Tissue Distribution After Donor-Specific Transfusion and Costimulatory Blockade.Transplantation direct · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
We have shown previously that collagen V (col(V)) autoimmunity is a consistent feature of atherosclerosis in human coronary artery disease and in the Apoe(-/-) mouse model. We have also shown sensitization of Apoe(-/-) mice with col(V) to markedly increase the atherosclerotic burden, providing evidence of a causative role for col(V) autoimmunity in atherosclerotic pathogenesis. Here we sought to determine whether induction of immune tolerance to col(V) might ameliorate atherosclerosis, providing further evidence for a causal role for col(V) autoimmunity in atherogenesis and providing insights into the potential for immunomodulatory therapeutic interventions. Mucosal inoculation successfully induced immune tolerance to col(V) with an accompanying reduction in plaque burden in Ldlr(-/-) mice on a high-cholesterol diet. The results therefore demonstrate that inoculation with col(V) can successfully ameliorate the atherosclerotic burden, suggesting novel approaches for therapeutic interventions. Surprisingly, tolerance and reduced atherosclerotic burden were both dependent on the recently described IL-35 and not on IL-10, the immunosuppressive cytokine usually studied in the context of induced tolerance and amelioration of atherosclerotic symptoms. In addition to the above, using recombinant protein fragments, we were able to localize two epitopes of the α1(V) chain involved in col(V) autoimmunity in atherosclerotic Ldlr(-/-) mice, suggesting future courses of experimentation for the characterization of such epitopes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.